Published in J Intern Med on March 01, 2014
SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid | NCT03954210
Stress, Meditation, and Alzheimer's Disease Prevention: Where The Evidence Stands. J Alzheimers Dis (2015) 1.50
Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders. Eur J Heart Fail (2015) 1.46
Advances in the prevention of Alzheimer's Disease. F1000Prime Rep (2015) 0.89
Amyloid PET imaging: applications beyond Alzheimer's disease. Clin Transl Imaging (2015) 0.88
Vascular factors and multiple measures of early brain health: CARDIA brain MRI study. PLoS One (2015) 0.88
Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research. Alzheimers Res Ther (2015) 0.83
Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (2015) 0.83
Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. J Am Med Dir Assoc (2015) 0.82
Detection of Outliers Due to Participants' Non-Adherence to Protocol in a Longitudinal Study of Cognitive Decline. PLoS One (2015) 0.81
Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. J Alzheimers Dis (2016) 0.81
A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. Alzheimers Res Ther (2016) 0.81
Changing Behavioral Lifestyle Risk Factors Related to Cognitive Decline in Later Life Using a Self-Motivated eHealth Intervention in Dutch Adults. J Med Internet Res (2016) 0.79
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis (2014) 0.78
The Empowering Role of Mobile Apps in Behavior Change Interventions: The Gray Matters Randomized Controlled Trial. JMIR Mhealth Uhealth (2016) 0.78
Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementia. Alzheimers Res Ther (2015) 0.78
Captopril and Valsartan May Improve Cognitive Function Through Potentiation of the Brain Antioxidant Defense System and Attenuation of Oxidative/Nitrosative Damage in STZ-Induced Dementia in Rat. Adv Pharm Bull (2016) 0.77
Marital Status, Lifestyle and Dementia: A Nationwide Survey in Taiwan. PLoS One (2015) 0.76
Dementia: The rising global tide of cognitive impairment. Nat Rev Neurol (2016) 0.76
Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of Neurodegenerative Disorders. J Alzheimers Dis (2016) 0.76
Evaluation of the influence of metabolic processes and body composition on cognitive functions: Nutrition and Dementia Project (NutrDem Project). Eur J Clin Nutr (2014) 0.76
Bridging the Translation Gap: From Dementia Risk Assessment to Advice on Risk Reduction. J Prev Alzheimers Dis (2015) 0.76
Aβ vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, Aβ, and microhemorrhages. Neurobiol Aging (2016) 0.75
Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement (Amst) (2017) 0.75
An Australian survey of cognitive health beliefs, intentions, and behaviours through the adult life course. Prev Med Rep (2015) 0.75
Analyzing the genes related to Alzheimer's disease via a network and pathway-based approach. Alzheimers Res Ther (2017) 0.75
Development of a Late-Life Dementia Prediction Index with Supervised Machine Learning in the Population-Based CAIDE Study. J Alzheimers Dis (2016) 0.75
Predicting dementia in primary care patients with a cardiovascular health metric: a prospective population-based study. BMC Neurol (2016) 0.75
Protective Effect of 17β-Estradiol Upon Hippocampal Spine Density and Cognitive Function in an Animal Model of Vascular Dementia. Sci Rep (2017) 0.75
Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology (2017) 0.75
On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther (2017) 0.75
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? Proc R Soc Med (1965) 40.52
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology (2007) 9.27
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol (2011) 8.15
Age, neuropathology, and dementia. N Engl J Med (2009) 6.36
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol (2009) 5.37
Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol (1988) 5.18
Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med (2012) 5.12
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol (2009) 4.96
The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol (2005) 4.54
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol (2012) 4.25
Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology (2012) 3.47
Loneliness and risk of Alzheimer disease. Arch Gen Psychiatry (2007) 3.44
The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol (2006) 3.38
Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ (2010) 3.37
Relation of cognitive activity to risk of developing Alzheimer disease. Neurology (2007) 3.34
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ (2000) 3.30
Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol (2008) 3.28
National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline. Ann Intern Med (2010) 3.24
Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology (2013) 3.20
Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA (2002) 3.16
Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol (2012) 2.65
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology (2007) 2.54
Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol (2005) 2.52
Statins for the prevention of dementia. Cochrane Database Syst Rev (2009) 2.38
The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology (2009) 2.33
Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. Arch Gen Psychiatry (2007) 2.02
Association between mid-life marital status and cognitive function in later life: population based cohort study. BMJ (2009) 2.00
Brain reserve hypothesis in dementia. J Alzheimers Dis (2007) 1.99
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci (2002) 1.83
Making Alzheimer's and dementia research fit for populations. Lancet (2012) 1.76
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Modelling age-specific risk: application to dementia. Stat Med (1998) 1.74
Education, the brain and dementia: neuroprotection or compensation? Brain (2010) 1.68
Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiol Aging (2005) 1.66
Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol (2012) 1.65
Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev (2009) 1.56
Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. Neurology (2013) 1.51
Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol (2008) 1.49
'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci (2010) 1.47
Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol (2011) 1.32
Effect of purpose in life on the relation between Alzheimer disease pathologic changes on cognitive function in advanced age. Arch Gen Psychiatry (2012) 1.26
Cognitive reserve, presynaptic proteins and dementia in the elderly. Transl Psychiatry (2012) 1.22
Association or causation: evaluating links between "environment and disease". Bull World Health Organ (2005) 1.21
Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer (2010) 1.21
Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension (2012) 1.16
Alzheimer's research. Stopping Alzheimer's before it starts. Science (2012) 1.09
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement (2013) 1.07
Midlife vascular risk factors and Alzheimer's disease: evidence from epidemiological studies. J Alzheimers Dis (2012) 1.07
Methodological challenges in designing dementia prevention trials - the European Dementia Prevention Initiative (EDPI). J Neurol Sci (2012) 1.04
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag (2010) 1.04
Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement (2009) 1.02
A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. J Nutr Health Aging (2013) 1.00
Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord (2009) 0.99
Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens (2013) 0.98
Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement (2011) 0.97
Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). J Nutr Health Aging (2012) 0.95
Prevention of cognitive decline in ageing: dementia as the target, delayed onset as the goal. Lancet Neurol (2011) 0.93
Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment. BMC Neurol (2010) 0.92
Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. J Alzheimers Dis (2012) 0.91
Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs (2012) 0.91
Dementia in the oldest old. Nat Rev Neurol (2013) 0.86
The European Dementia Prevention Initiative. Lancet Neurol (2013) 0.84
The Alzheimer myth and biomarker research in dementia. J Alzheimers Dis (2012) 0.84
Effects of selenium supplements on cancer prevention: meta-analysis of randomized controlled trials. Nutr Cancer (2011) 0.82
Prevalence of cardiovascular disorders and risk factors in two 75-year-old birth cohorts examined in 1976-1977 and 2005-2006. Aging Clin Exp Res (2013) 0.78
Preventing Alzheimer disease and cognitive decline. Ann Intern Med (2011) 0.78
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med (1997) 7.56
Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging (2009) 5.98
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med (1992) 5.93
MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging (2001) 4.54
APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology (1999) 4.37
Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology (2012) 4.09
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology (2006) 3.71
Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens (2003) 3.67
Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology (2004) 3.61
Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology (2003) 3.59
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology (2010) 3.58
Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology (2002) 3.40
Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 3.39
Description of 1,108 older patients referred by their physician to the "Geriatric Frailty Clinic (G.F.C) for Assessment of Frailty and Prevention of Disability" at the gerontopole. J Nutr Health Aging (2014) 3.37
Relation of cognitive activity to risk of developing Alzheimer disease. Neurology (2007) 3.34
Diagnosis and treatment of depression in late life. Consensus statement update. JAMA (1997) 3.14
Development of the EURO-D scale--a European, Union initiative to compare symptoms of depression in 14 European centres. Br J Psychiatry (1999) 3.13
A 24-year follow-up of body mass index and cerebral atrophy. Neurology (2004) 2.91
Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care (2004) 2.77
Cognitive activity and incident AD in a population-based sample of older persons. Neurology (2002) 2.77
Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology (2007) 2.72
Depressive symptoms and cognitive decline in a community population of older persons. J Neurol Neurosurg Psychiatry (2004) 2.67
Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol (1991) 2.63
Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology (2003) 2.60
Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology (2007) 2.56
Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. Neurology (2002) 2.52
Burden of illness and suicide in elderly people: case-control study. BMJ (2002) 2.51
Change in body mass index and risk of incident Alzheimer disease. Neurology (2005) 2.48
Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology (2006) 2.48
MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology (2005) 2.48
Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 2.45
Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. J Nutr Health Aging (2013) 2.44
Neurodegenerative basis of age-related cognitive decline. Neurology (2010) 2.41
The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol (2000) 2.37
Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol (1991) 2.36
Chronic distress and incidence of mild cognitive impairment. Neurology (2007) 2.33
A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns]. Arch Gen Psychiatry (1999) 2.31
Cognitive activity in older persons from a geographically defined population. J Gerontol B Psychol Sci Soc Sci (1999) 2.31
Parkinsonian signs in subjects with mild cognitive impairment. Neurology (2005) 2.30
MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging (2004) 2.29
Body mass index and the risk of Parkinson disease. Neurology (2006) 2.28
Kidney function is associated with the rate of cognitive decline in the elderly. Neurology (2009) 2.27
Education and dementia: what lies behind the association? Neurology (2007) 2.26
Onset of terminal decline in cognitive abilities in individuals without dementia. Neurology (2008) 2.24
Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ (1996) 2.20
Terminal decline in cognitive function. Neurology (2003) 2.18
Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology (2005) 2.13
Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology (2000) 2.10
Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology (2004) 2.10
High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology (2005) 2.07
Total cholesterol and the risk of Parkinson disease. Neurology (2008) 2.06
Cognitive activity and cognitive decline in a biracial community population. Neurology (2003) 2.06
Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry (1990) 2.05
Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology (2001) 2.04
Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry (2000) 1.97
Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology (2008) 1.97
Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology (2010) 1.88
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Depressive symptoms and risk of stroke: the Rotterdam Study. J Neurol Neurosurg Psychiatry (2008) 1.84
Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology (2011) 1.84
Stability of the preclinical episodic memory deficit in Alzheimer's disease. Brain (2001) 1.83
Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology (2007) 1.81
A voxel based morphometry study on mild cognitive impairment. J Neurol Neurosurg Psychiatry (2005) 1.79
Prognosis with dementia in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 1.76
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Depression symptoms in late life assessed using the EURO-D scale. Effect of age, gender and marital status in 14 European centres. Br J Psychiatry (1999) 1.75
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 1.75
Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop (2007) 1.74
Proneness to psychological distress and risk of Alzheimer disease in a biracial community. Neurology (2005) 1.70
Terminal dedifferentiation of cognitive abilities. Neurology (2012) 1.68
The primary care physician and Alzheimer's disease: an international position paper. J Nutr Health Aging (2010) 1.68
Memory complaints are related to Alzheimer disease pathology in older persons. Neurology (2006) 1.67
The occurrence of depressive symptoms in the preclinical phase of AD: a population-based study. Neurology (1999) 1.67
Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology (2010) 1.67
Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology (2011) 1.66
Mild cognitive impairment: a concept in evolution. J Intern Med (2014) 1.65
Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology (2001) 1.64
The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology (2010) 1.64
The impact of chronic multimorbidity and disability on functional decline and survival in elderly persons. A community-based, longitudinal study. J Intern Med (2009) 1.57
Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD Expert Meeting. J Nutr Health Aging (2013) 1.57
The apolipoprotein E epsilon 2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry (2002) 1.57
Diabetes mellitus, dementia, and cognitive function in older persons. J Nutr Health Aging (2006) 1.56
Body mass index in older persons is associated with Alzheimer disease pathology. Neurology (2006) 1.55
The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction [corrected] detected at autopsy in older persons. Stroke (2005) 1.55
Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol (1999) 1.55
The relationship between cerebral Alzheimer's disease pathology and odour identification in old age. J Neurol Neurosurg Psychiatry (2006) 1.55
Institutionalization in the elderly: the role of chronic diseases and dementia. Cross-sectional and longitudinal data from a population-based study. J Clin Epidemiol (2001) 1.54
Change in frailty and risk of death in older persons. Exp Aging Res (2009) 1.54
The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 1.53
Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. Am J Public Health (1998) 1.51
Little evidence for different phenomenology in poststroke depression. Acta Psychiatr Scand (2010) 1.50